
Corcept Therapeutics (CORT) Stock Forecast & Price Target
Corcept Therapeutics (CORT) Analyst Ratings
Bulls say
Corcept Therapeutics is supported by a strengthening multi-product franchise, with 1Q26 revenues of approximately $165M and full-year guidance raised to a midpoint of $1B after positive early Lifyorli launches and record Korlym patient starts in March and April. The company’s core Cushing’s business looks set to recover as the pharmacy transition ended in February 2026 and the new vendor clears prior-authorizations, removing a key volume bottleneck. Its long-term upside is reinforced by relacorilant’s positive CHMP opinion for platinum-resistant ovarian cancer, superior ROSELLA efficacy, and a promising FDA resubmission path for Cushing’s syndrome that could further broaden the growth base.
Bears say
Corcept Therapeutics is viewed negatively because its valuation and operating outlook still depend heavily on a narrow set of products and pipeline catalysts, leaving the company exposed if relacorilant or other programs disappoint. While the resubmission announcement improves visibility on a regulatory path and suggests a potential second approval by YE 2026, the business still faces meaningful execution risk, with the prior base case assuming a new pivotal trial and a delayed commercial launch in 2029. Even with lower projected R&D expense and a pulled-forward launch to 2027, the investment case remains sensitive to clinical and regulatory outcomes rather than durable, diversified fundamentals.
This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction
Start investing in Corcept Therapeutics (CORT)
Order type
Buy in
Order amount
Est. shares
0 shares